- Home
- VIGL vs PLCE Comparison
VIGL vs PLCE Comparison
Compare VIGL & PLCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- PLCE
- Stock Information
- Founded
- VIGL 2020
- PLCE 1969
- Country
- VIGL United States
- PLCE United States
- Employees
- VIGL N/A
- PLCE N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- PLCE Clothing/Shoe/Accessory Stores
- Sector
- VIGL Health Care
- PLCE Consumer Discretionary
- Exchange
- VIGL Nasdaq
- PLCE Nasdaq
- Market Cap
- VIGL 89.3M
- PLCE 106.6M
- IPO Year
- VIGL 2022
- PLCE 1997
- Fundamental
- Price
- VIGL $1.68
- PLCE $8.59
- Analyst Decision
- VIGL Strong Buy
- PLCE Hold
- Analyst Count
- VIGL 5
- PLCE 3
- Target Price
- VIGL $16.33
- PLCE $8.33
- AVG Volume (30 Days)
- VIGL 159.5K
- PLCE 312.6K
- Earning Date
- VIGL 03-13-2025
- PLCE 04-11-2025
- Dividend Yield
- VIGL N/A
- PLCE N/A
- EPS Growth
- VIGL N/A
- PLCE N/A
- EPS
- VIGL N/A
- PLCE N/A
- Revenue
- VIGL N/A
- PLCE $1,432,740,000.00
- Revenue This Year
- VIGL N/A
- PLCE N/A
- Revenue Next Year
- VIGL N/A
- PLCE N/A
- P/E Ratio
- VIGL N/A
- PLCE N/A
- Revenue Growth
- VIGL N/A
- PLCE N/A
- 52 Week Low
- VIGL $1.49
- PLCE $4.77
- 52 Week High
- VIGL $6.06
- PLCE $19.74
- Technical
- Relative Strength Index (RSI)
- VIGL 32.05
- PLCE 49.27
- Support Level
- VIGL $1.74
- PLCE $8.35
- Resistance Level
- VIGL $1.94
- PLCE $9.47
- Average True Range (ATR)
- VIGL 0.16
- PLCE 0.68
- MACD
- VIGL -0.02
- PLCE 0.13
- Stochastic Oscillator
- VIGL 4.51
- PLCE 66.28
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.